Illustrative image – not actual.Ranbaxy Laboratories is investing $100 million (approx Rs.440 crore) during the current year for expanding the production capacity of its Indian, Brazilian and the US manufacturing facilities.
The investment would be for enhancement of the active pharmaceutical ingredient (API) and formulations capacities to meet the volume growth and extend the product pipeline.
Majority of the investment would go for company's manufacturing facilities for API and formulations in India and the balance for its two other major facilities in US and Brazil.
